Essential requirement for β-arrestin2 in mouse intestinal tumors with elevated Wnt signaling

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 8, 2012, Pages 3047-3052

  Bonnans, Caroline ^a,b,c   Flacelière, Maud ^a,b,c   Grillet, Fanny ^a,b,c   Dantec, Christelle ^a,b,c   Desvignes, Jean Pierre ^a,b,c   Pannequin, Julie ^a,b,c   Severac, Dany ^a,b,c   Dubois, Emeric ^a,b,c   Bibeau, Frédéric ^d   Escriou, Virginie ^e,f,g   Crespy, Philippe ^a,b,c   Journot, Laurent ^a,b,c   Hollande, Frédéric ^a,b,c   Joubert, Dominique ^a,b,c  

^a INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

^d CENTRE VAL D AURELLE   (France)

^e Centre National de la Recherche Scientifique   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g PSL RESEARCH UNIVERSITY   (France)

Author keywords

Carcinogenesis; Tumor initiation

Indexed keywords

BETA ARRESTIN 1; BETA ARRESTIN 2; MESSENGER RNA; SMALL INTERFERING RNA; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; EX VIVO STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; IMMUNOFLUORESCENCE; IN VIVO STUDY; INTESTINE CANCER; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; ARRESTINS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL PROLIFERATION; CELL SEPARATION; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTESTINAL NEOPLASMS; MICE; MICE, INBRED C57BL; TUMOR STEM CELL ASSAY; WNT SIGNALING PATHWAY;

EID: 84857433083     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1109457109     Document Type: Article

References (35)

1. Knudson AG (1996) Hereditary cancer: Two hits revisited. J Cancer Res Clin Oncol 122:135-140.
2. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789-799. (Pubitemid 39070849)
3. Powell SM, et al. (1992) APC mutations occur early during colorectal tumorigenesis. Nature 359:235-237.
4. Yamada Y, et al. (2002) Microadenomatous lesions involving loss of Apc heterozygosity in the colon of adult Apc(Min/+) mice. Cancer Res 62:6367-6370. (Pubitemid 35364087)
5. Lefkowitz RJ, Shenoy SK (2005) Transduction of receptor signals by beta-arrestins. Science 308:512-517.
6. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK (2007) Beta-arrestins and cell signaling. Annu Rev Physiol 69:483-510.
7. Mandell JW, et al. (2009) Dephosphorylation of beta-arrestin 1 in glioblastomas. J Neuropathol Exp Neurol 68:535-541.
8. Li TT, et al. (2009) Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol Cancer Res 7:1064-1077.
9. Dasgupta P, et al. (2006) Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 116:2208-2217. (Pubitemid 44162330)
10. Ahn S, Kim J, Hara MR, Ren XR, Lefkowitz RJ (2009) beta-Arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphorylation. J Biol Chem 284:8855-8865.
11. Rosanò L, et al. (2009) Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci USA 106:2806-2811.
12. Kovacs JJ, Hara MR, Davenport CL, Kim J, Lefkowitz RJ (2009) Arrestin development: Emerging roles for beta-arrestins in developmental signaling pathways. Dev Cell 17:443-458.
13. Chen W, et al. (2001) beta-Arrestin1 modulates lymphoid enhancer factor transcriptional activity through interaction with phosphorylated dishevelled proteins. Proc Natl Acad Sci USA 98:14889-14894. (Pubitemid 34013940)
14. Chen W, et al. (2003) Dishevelled 2 recruits beta-arrestin 2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4. Science 301:1391-1394. (Pubitemid 37075817)
15. Bryja V, Gradl D, Schambony A, Arenas E, Schulte G (2007) Beta-arrestin is a necessary component of Wnt/beta-catenin signaling in vitro and in vivo. Proc Natl Acad Sci USA 104:6690-6695. (Pubitemid 47175562)
16. Colnot S, et al. (2004) Colorectal cancers in a new mouse model of familial adenomatous polyposis: Influence of genetic and environmental modifiers. Lab Invest 84:1619-1630. (Pubitemid 39600569)
17. Conner DA, et al. (1997) beta-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation. Circ Res 81:1021-1026. (Pubitemid 27514952)
18. Bohn LM, et al. (1999) Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286:2495-2498.
19. Smyth G (2005) Bioinformatics and Computational Biology Solutions using R and Bioconductor, eds Gentleman R, et al. (Springer, New York), pp 397-420.
20. Barker N, et al. (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449:1003-1007. (Pubitemid 350014593)
21. Buchert M, et al. (2010) Genetic dissection of differential signaling threshold requirements for the Wnt/beta-catenin pathway in vivo. PLoS Genet 6:e1000816.
22. Albuquerque C, et al. (2002) The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum Mol Genet 11:1549-1560. (Pubitemid 34679255)
23. Cheung AF, et al. (2010) Complete deletion of Apc results in severe polyposis in mice. Oncogene 29:1857-1864.
24. Metcalfe C, et al. (2010) Dvl2 promotes intestinal length and neoplasia in the ApcMin mouse model for colorectal cancer. Cancer Res 70:6629-6638.
25. King TE, et al. (2008) The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model. PLoS ONE 3:e3535.
26. Ray PS, et al. (2010) FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res 70:3870-3876.
27. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174. (Pubitemid 37328786)
28. Petrova TV, et al. (2008) Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell 13:407-419. (Pubitemid 351609440)
29. Sinner D, et al. (2007) Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol 27:7802-7815. (Pubitemid 350086414)
30. Darido C, et al. (2008) Defective claudin-7 regulation by Tcf-4 and Sox-9 disrupts the polarity and increases the tumorigenicity of colorectal cancer cells. Cancer Res 68:4258-4268.
31. Buchert M, et al. (2010) Symplekin promotes tumorigenicity by up-regulating claudin-2 expression. Proc Natl Acad Sci USA 107:2628-2633.
32. Deka J, et al. (2010) Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. Cancer Res 70:6619-6628.
33. Yu MC, et al. (2008) An essential function for beta-arrestin 2 in the inhibitory signaling of natural killer cells. Nat Immunol 9:898-907.
34. Rhinn H, et al. (2009) How to make siRNA lipoplexes efficient? Add a DNA cargo. Biochim Biophys Acta 1790:219-230.
35. Gerbe F, et al. (2011) Distinct ATOH1 and Neurog3 requirements define tuft cells as a new secretory cell type in the intestinal epithelium. J Cell Biol 192:767-780.